Modality
Fusion Protein
MOA
CFTRmod
Target
CD38
Pathway
Tau
FSGSEwing SarcomaNB
Development Pipeline
Preclinical
~Jun 2023
→ ~Sep 2024
Phase 1
Dec 2024
→ Nov 2025
Phase 1Current
NCT05156489
2,123 pts·NB
2024-12→2025-11·Active
2,123 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-214mo agoInterim· NB
Trial Timeline
2025Q2Q3Q4
P1
Active
Catalysts
Interim
2025-11-21 · 4mo ago
NB
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05156489 | Phase 1 | NB | Active | 2123 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |